Your making assumptions that people are 'trapped'....
Perhaps they are investors taking a long term view of this Companies potential with it's current research pipeline into a range of difficult to treat Cancer types. Perhaps they see the Company as being undervalued at a $39 Million MC compared to peers in the Biomedical space?
Perhaps they've done their research and invested wisely and are happy to wait the outcome of upcoming trials due for release in coming weeks that may in fact rerate the Company significantly?
• Complete Phase 2 (part1) of PTX-200 in breast cancer ON TRACK FOR Q4
• Complete Phase 1b PTX-200 in Ovarian cancer ON TRACK FOR Q4
A positive outcome on either of the above trials will lead to a significant rerate of PTX in my humble opinion.
Company is well funded with about $10 Million in the bank after recent R&D tax refund from Government.
Ann: Third complete response in PTX-200 AML Trial, page-203
-
- There are more pages in this discussion • 155 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
